Dark web drug markets nearly doubled in size over the past year. Prevention barely kept pace. That’s the real story inside a new bulletin from the Drug Trends programme at the National Drug and Alcohol Research Centre (NDARC), UNSW Sydney. Researchers tracked nineteen cryptomarkets from June 2025 to May 2026. Total drug listings climbed from 26,462 to 55,785, a jump of roughly 2.8 percent a month. Three markets closed along the way. Seven new ones opened to replace them. The report counts listings, tracks closures, and measures market share down to a tenth of a percent. It never quite asks where prevention and demand reduction fit into any of this. That gap is, in a lot of ways, the real headline.

Cannabis Still Dominates, and Nobody Is Asking Why Demand Keeps Rising

Cannabis makes up 25.2 percent of listings across the full year, the largest single category by a wide margin. Its share climbed from 24.9 percent in June 2025 to 26.2 percent in May 2026, growing 1.5 percent a month. That’s happening even as legal and semi legal cannabis markets expand in plenty of places around the world. Opioids excluding heroin come in next at 7.3 percent. Benzodiazepines and MDMA each sit at 7.2 percent, cocaine at 6.9 percent, and performance and image enhancing drugs at 6.8 percent. Six broad categories, all with steady buyers, none of them shrinking in any meaningful way. A market this varied and durable isn’t a supply problem waiting on the next seizure. It’s a demand problem nobody has funded an answer for. Online drug marketplaces like these don’t shrink on their own.

Two Marketplaces Break the Ten Thousand Listing Mark, and Enforcement Barely Slows Them

Two cryptomarkets reached extraordinary size. Drughub peaked at 14,386 listings in a single snapshot in May 2026. Torzon reached 10,479 that same month. Nexus, MarsMarket and Blackops joined them as the five biggest sites in the final month of monitoring. Each sat well above the average of 3,719 listings per market. A sixth market, Dark Matter, had climbed as high as 9,260 listings earlier in the year. Changes to its website then kept researchers from finishing a scrape in the final months. Markets don’t reach this kind of scale by accident. Buyers keep coming back, month after month, and nothing about the current response changes that before it starts.

Heroin Listings Climb Fastest, and It’s the Clearest Case for Prevention Funding

Cannabis holds the biggest overall share, but heroin recorded the steepest relative growth of any drug tracked. It’s the clearest case for prevention funding on dark web drug markets. Heroin’s market share rose 1.7 percent a month. It climbed from 2.1 percent in June 2025 to a peak of 2.6 percent in March and April 2026. That climb eased back to 2.2 percent in May. The raw number of listings more than doubled, from 556 to 1,252, a jump of 4.5 percent a month. Heroin carries some of the best documented overdose and dependence risks of any drug in the report. A trend line this steep, for a drug this dangerous, should trigger early intervention and honest conversations with families. Instead, the report logs the number in a table and moves on to the next substance.

Cocaine, LSD and Hallucinogens Are Rising Too, and Each One Is a Missed Window

Heroin wasn’t the only substance trending upward. Cocaine listings rose from 1,842 to 3,954, a jump of 3.6 percent a month. Hallucinogenic mushroom listings climbed 4.4 percent a month, from 658 to 1,438. LSD rose 4.0 percent a month, from 1,032 to 1,834. New psychoactive substances made up a further 5.3 percent of all listings. That’s a fast moving category of emerging synthetic compounds. The report’s authors suspect they haven’t fully counted it yet, since new substances show up faster than researchers can catalogue them. Every one of these upward curves tells the same story five different ways. Prevention education could have reached someone before they ever went looking for a cryptomarket. That window closed without anyone stepping through it.

Benzodiazepines and GHB Losing Share, but the Overall Market Still Grew

Not every category grew. Benzodiazepines, including alprazolam, diazepam, clonazepam and zolpidem, showed the sharpest decline in market share of any drug class. It fell 4.2 percent a month. That’s a drop from 8.1 percent in June 2025 to a low of 4.6 percent in April 2026. It then climbed right back up to 8.1 percent by May. GHB, GBL and 1,4 BD fell 3.3 percent a month, from 0.6 percent to 0.4 percent of listings. Opioids excluding heroin dropped 2.3 percent a month, from 8.0 percent to 6.7 percent. On the surface, a falling share looks like progress. It really isn’t. The overall market nearly doubled across the same stretch of time. So even the categories losing ground are still reaching more buyers in raw numbers than they were a year earlier. That’s the trap with dark web drug markets: percentages can fall while real harm keeps climbing.

Enforcement Can Close a Market, but It Can’t Touch the Demand That Built It

Three of the nineteen cryptomarkets monitored closed during the reporting period. MGM Grand exited on its own terms. Elysium disappeared in what researchers describe as an exit scam. Ares closed for reasons that still aren’t known. None of it slowed overall growth. Seven new markets opened to take their place, three in January 2026 and four more in May 2026. Researchers also dropped two further sites from monitoring after the community reported them as scam markets full of fake listings. This is what a supply only response looks like in practice. Enforcement can shut down vendors and platforms one at a time. Yet the total number of listings nearly doubled anyway. Closing a marketplace does nothing to reduce the demand that built it. It also does nothing to stop a new one from opening to meet that same demand the next month.

Prevention and Demand Reduction Deserve Equal Billing

Read start to finish, the NDARC bulletin is meticulous about scale, categories and closures. It says almost nothing about solutions. This report documents market size, tracks drug categories to fractions of a percent, and logs every closure and replacement. Nowhere does it address what might actually shrink demand for any of it. That gap matters. Every listing on these dark web drug markets represents a substance that can reach a buyer. That buyer is often a young person, with no age check and no quality control.

As cryptomarkets grow bigger and more resistant to closures, supply side enforcement on its own will keep losing ground. Prevention education, honest family conversations and early intervention are still missing from the picture. That’s true both in this bulletin and in too much of the public conversation around online drug marketplaces. Sustained investment in that work could reduce demand. It could reach a young person before they ever start searching for a cryptomarket in the first place. Data like this should push funders toward that goal. Right now it’s just a running tally of how big the problem has gotten.

Source: unsw